PITNEY-BOWES-INC.
14.7.2020 14:02:10 CEST | Business Wire | Press release
Pitney Bowes (NYSE: PBI), a global technology company that provides commerce solutions in the areas of shipping, mailing, data and ecommerce, today announced the election of Sheila A. Stamps to its board of directors, effective September 1, 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200714005558/en/
“We are pleased to welcome Sheila Stamps to the Pitney Bowes Board of Directors,” said Marc B. Lautenbach, President and CEO, Pitney Bowes. “Sheila brings significant business, banking and accounting expertise in both the private and public sector to our Company. Throughout her career, Sheila has played key roles in helping companies transform and grow. We look forward to having her perspective as we further strengthen and diversify our Board.”
The election of Ms. Stamps to the Pitney Bowes board of directors will bring the total number of directors to 10. Ms. Stamps will serve on the Audit and Executive Compensation Committees.
About Sheila A. Stamps
Sheila A. Stamps currently serves on the boards of Atlas Air Worldwide Holdings, Inc. (Audit Chair), and CIT Group, Inc. and CIT Bank, N.A. She is also a member of the Board of Directors of IES Abroad, a non-profit organization facilitating global educational opportunities and internships. She is a former Commissioner and Audit Committee Chair for the board of the New York State Insurance Fund, the State’s largest worker's compensation insurance provider.
Previously she served as Executive Vice President at DBI, LLC, a private mortgage investment company, from 2011 to 2012. She served from 2008 to 2011 as Director of Pension Investments and Cash Management at the New York State Common Retirement Fund, and from 2004 to 2005 as a Fellow at the Weatherhead Center for International Affairs at Harvard University.
Prior to this, Ms. Stamps served as Managing Director and Head of Relationship Management, Financial Institutions, at Bank of America Corp. (formerly FleetBoston). From 1982 to 2003, she held several executive positions both domestically and internationally with Bank One Corp. (now JPMorgan), including Managing Director and Head of European Asset-Backed Securitization and a member of the EMEA Strategic Operating Committee. She holds an MBA in Finance from the University of Chicago.
About Pitney Bowes
Pitney Bowes (NYSE:PBI) is a global technology company providing commerce solutions that power billions of transactions. Clients around the world, including 90 percent of the Fortune 500, rely on the accuracy and precision delivered by Pitney Bowes solutions, analytics, and APIs in the areas of ecommerce fulfillment, shipping and returns; cross-border ecommerce; office mailing and shipping; presort services; and financing. For 100 years Pitney Bowes has been innovating and delivering technologies that remove the complexity of getting commerce transactions precisely right. For additional information visit Pitney Bowes, the Craftsmen of Commerce, at www.pitneybowes.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200714005558/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Chiesi Group appoints Paolo Paoletti to its Board of Directors29.10.2026 11:01:00 CET | Press release
HIGHLIGHTS:Paolo Paoletti, M.D., joins Chiesi's Board of Directors as its fourth independent member, effective as of today.An internationally recognized pharmaceutical leader, he brings more than 30 years of experience spanning R&D, biotechnology innovation and global healthcare leadership.His appointment further strengthens the Board's scientific and strategic expertise as Chiesi advances its commitment to delivering innovative solutions for patients. Chiesi, the international research-focused biopharmaceutical group, today announced the appointment of Paolo Paoletti, M.D. to its Board of Directors, effective as of today. Paoletti is an internationally recognized pharmaceutical executive with more than 30 years of experience across research and development, corporate leadership and biotechnology innovation. Throughout his career, he has held senior leadership positions at Lilly, GlaxoSmithKline (GSK) and GammaDelta Therapeutics, contributing to the development and commercialization of
Icon Solutions Appoints Raquel Guillot as Southern Europe Sales Director to Drive Global Adoption of the Icon Payments Framework29.10.2026 10:30:00 CET | Press release
Madrid-based appointment will focus on expanding the company’s presence across Southern Europe and developing opportunities in new markets Icon Solutions – the UK fintech enabling banks globally to design and implement state-of-the-art payment systems – has appointed Raquel Guillot as Southern Europe Sales Director, to drive adoption of the Icon Payments Framework (IPF) across the region. Guillot brings around 20 years of experience spanning banking, analytics, fraud prevention, payments and core banking technology. She began her career at Citibank before moving into financial technology, holding roles at SAS, ACI Worldwide and other technology providers, including Thought Machine. IPF is the internationally proven payments development framework trusted by banks across the globe, including Citi, UBS, NatWest and BNP Paribas. It enables banks to transform their systems in an accelerated, structured and low-risk way, all on their own terms. Based in Madrid, Guillot will focus on expandin
Alushibe Holding Group to Bring 12 Global F&B Brands to Libya by 202829.10.2026 09:00:00 CET | Press release
Ahmed Gadalla signs exclusive master franchise agreement with Türkiye's MADO: US$7 million, 7 cafés and 350 jobs in the first phase; 1,000 sq m Benghazi flagship opens Q1 2027 Alushibe Holding Group today announced plans to bring 12 international food-and-beverage brands to Libya by 2028 through its Retail & Destinations division, beginning with an exclusive master franchise agreement with MADO, the Turkish ice-cream and patisserie house founded in 1850. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261029822317/en/ Ahmed Gadalla signs exclusive master franchise agreement with Türkiye's MADO: US$7 million, 7 cafés and 350 jobs in the first phase; 1,000 sq m Benghazi flagship opens Q1 2027 – (Photo: AETOSWire) Signed in Kahramanmaraş on 13 October 2026 by Ahmed Gadalla, Founder and Chairman of Alushibe Holding Group, and Mehmet Sait Kanbur, Chairman of MADO, the agreement grants Alushibe exclusive rights to develop and opera
U.S. Bancorp Announces New U.S. Bancorp Global Funds Brand29.10.2026 09:00:00 CET | Press release
The platform also introduces its first offshore liquidity fund, domiciled in Ireland U.S. Bancorp today announced its new fund platform, U.S. Bancorp Global Funds, and its first offering, an offshore liquidity fund domiciled in Ireland, the U.S. Bancorp Liquidity – USD Treasury CNAV Fund. U.S. Bancorp Global Funds was created to support U.S. Bancorp’s growing international presence. It establishes a framework for future investment offerings and reflects U.S. Bancorp’s expanding presence in global markets. Investment products offered under the brand are established through U.S. Bancorp Global Funds ICAV, an Ireland-domiciled UCITS umbrella fund structure. The U.S. Bancorp Liquidity – USD Treasury CNAV Fund is the first offering introduced under the new brand. The U.S. Bancorp Liquidity – USD Treasury CNAV Fund is designed for investors outside the United States seeking to preserve capital while accessing a U.S. Treasury-focused liquidity solution within a regulated offshore structure. D
Element Biosciences Launches AVITI Dx™, Bringing CE-Marked IVD Sequencing to Ten EU Countries29.10.2026 09:00:00 CET | Press release
Integrated sequencing, reagents, and software bring IVDR-compliant sequencing capabilities to European clinical laboratories, with additional global markets planned to follow Element Biosciences, Inc. today announced the commercial launch of AVITI Dx, the company's first CE-marked in vitro diagnostic (IVD) sequencing platform under the European Union's In Vitro Diagnostic Regulation (EU IVDR). AVITI Dx integrates Element’s AVITI™ sequencing system, dedicated reagents, and software designed to meet applicable IVDR requirements and support regulated clinical laboratory workflows. The system is launching commercially in ten EU countries: the Netherlands, Germany, France, Italy, Spain, Austria, the Czech Republic, Latvia, Romania, and Poland, with additional markets planned through a phased approach. Developed and manufactured under Element's ISO 13485-certified quality management system, AVITI Dx is a Class A IVD sequencing system supported by IVDR-compliant reagents and software. Built o
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
